The in vitro activity of a new crystalline derivative of thienamycin, N-formimidoyl thienamycin (MK0787), was tested against 46 laboratory reference strains and 2,158 clinical isolates of gram-positive and -negative bacteria, including anaerobes, and compared with cefoxitin, cefazolin, carbenicillin, and amikacin. MK0787 was significantly more active than the reference antibiotics against most bacteria tested. MK0787 was 16-to 500-fold more active than the other antibiotics against Staphylococcus aureus, Streptococcus pneumoniae, and group A and group B streptococci, inhibiting most isolates at concentrations less than 0.031 ,ug/ml. The inhibition concentration against over 90% of 156 strains of Streptococcus faecalis was 1 yg/ml. MK0787 had slightly less activity than carbenicillin against Haemophilus influenzae. The minimal inhibitory concentrations of MK0787 against strains of Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Clostridium difficile that are resistant to currently available antibiotics were less than or equal to 4 ,ug/ml. The only species found resistant to MK0787 was Pseudomonas maltophilia, which was equally nonsusceptible to the other reference antibiotics.
ICAAC, abstr. no. 231) showed it to have at least equal and often superior in vitro and in vivo activity relative to thienamycin (1, 4, 5) . The present study was undertaken to investigate the activity ofthis new compound against a variety of bacterial strains and to compare it with cefoxitin, cefazolin, carbenicillin, and axnikacin, all of which are in current clinical use.
MATERIALS AND METHODS
Organisms. All The strains of Neisseria gonorrhoeae were grown on chocolate agar plates, and colonies were suspended in Trypto-soy broth just before dilution.
Mueller-Hinton agar (BBL Microbiology Systems) was used for susceptibility determinations unless otherwise specified. This medium supplemented with 5% sheep blood and Brucella agar (BBL Microbiology Systems) supplemented with 5% sheep blood and 10 ug of hemin per ml were used for determining the susceptibilities of streptococci and anaerobes, respectively. Chocolate Mueller-Hinton agar was used for H. influenzae and N. gonorrhoeae. An inoculum prepared by dilution of a fresh overnight broth culture was placed on susceptibility testing plates with a 27-prong metal replicater (Microplanter, Sakuma Seisakusho, Ltd.) of which each inoculation prong was Plates were incubated for 18 to 24 h at 37°C. Anaerobes and N. gonorrhoeae were incubated for 48 h at 37°C in GasPak jars (BBL Microbiology Systems) and candle extinction jars, respectively. Brucella agar plates used for susceptibility of Clostridium difficile were exposed to an atmospere of 80% N2, 10% H2, and 10% C02 in an anaerobic chamber (Hirayama Seisakusho, Ltd.) for 24 h at room temperature. C. difficile was then incubated in the anaerobic chamber for 48 h at 370C in the above gas mixture.
Serial twofold dilutions of the antibiotics were prepared daily in 0.01 M phosphate buffer (pH 7.0).
MIC was defined as the lowest concentration that showed no growth, or less than five isolated colonies, or a faint haze.
RESULTS
The comparative in vitro activities of MK0787 against 2,158 individual patient clinical isolates are shown in Table 1 , as well as those of cefoxitin, cefazolin, carbenicillin, and amikacin. The identification of all isolates was confirmed in our ANTIMICROB. AGENTS CHEMOTHER.
laboratory. MK0787 exerted a high degree of inhibitory activity against staphylococci and streptococci, being 4-to 258-fold more potent than the reference antibiotics, and the great majority of isolates were susceptible to 0.031 ,ug or less of MK0787 per ml. A total of 96% of Streptococcus faecalis isolates tested were inhibited by 1 jig of MK0787 per ml, whereas carbenicillin inhibited only 1.2% at this concentration. MK0787 inhibitied 90% of 73 strains of H. influenzae at 2 ,ug/ml, indicating that MK0787 was slightly less active than carbenicillin, but was two-to eightfold more active than cefoxitin, amikacin, and cefazolin. Table 2 summarizes the MICs of MK0787 and the reference compounds against laboratory strains of 28 gram-positive and -negative bacterial species, including anaerobes, which were not included among the individual patient clinical isolates. MK0787 exhibited a potent and broadspectrum activity and was clearly more active than the reference antibiotics against all strains Table 2 , laboratory strains of 18 species that were also present among the individual patient isolates were evaluated. The MICs observed with the laboratory strains fell within the range of susceptibilities observed with the clinical isolates. No significant inactivation of MK0787 by culture filtrates, whole cells, or cell-free extracts of P. maltophilia could be demonstrated in preliminary studies. This result suggests that fl-lactamase does not play a role in the resistance mechanism of P. maltophilia.
The in vitro data on MK0787 activity in the present study suggest that it can be used in the treatment of wide variety of infections, rarely requiring a supplemental use of narrow-spectrum antibiotic.
Another important early observation is the activity of MK0787 against anaerobes. The in vitro activity of MK0787 was greater against six species of anaerobes than other antibiotics. 
